Childhood Laryngeal Tumors Treatment (PDQ®)–Health Professional Version

SECTIONS

Changes to This Summary (09/21/2018)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

This summary was comprehensively reviewed and reformatted.

Childhood Laryngeal Papillomatosis

Added text to state that the role of checkpoint inhibitors, such as PD-1 inhibitors, is currently being investigated (cited Ivancic et al. as reference 10). Also added text to state that in selected patients, administration of a quadrivalent human papillomavirus vaccine has been associated with complete and partial remissions after initial surgery and increased intersurgical intervals (cited Young et al. as reference 11).

Added Treatment Options Under Clinical Evaluation for Childhood Laryngeal Papillomatosis as a new subsection.

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Special Considerations for the Treatment of Children With Cancer

Next section >
About This PDQ Summary